Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 7, 2013, Pages 1341-1343

  Matsuo, Yusuke ^a   Mizoguchi, Fumitaka ^a   Kohsaka, Hitoshi ^a   Ito, Eisaku ^a   Eishi, Yoshinobu ^a   Miyasaka, Nobuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISOLONE; TOCILIZUMAB;

ADULT; ANTIGEN ANTIBODY COMPLEX; CASE REPORT; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; ELECTRON MICROSCOPY; ERYTHROCYTE; HEMATURIA; HUMAN; IMMUNE COMPLEX NEPHRITIS; KIDNEY BIOPSY; LETTER; MALE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN URINE LEVEL; PROTEINURIA; RHEUMATOID ARTHRITIS; URINALYSIS;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BIOPSY; DNA; FEMALE; GLOMERULONEPHRITIS; HUMANS; MIDDLE AGED;

EID: 84879820208     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes403     Document Type: Letter

References (9)

1. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
2. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371: 987-97.
3. Nishimoto N, Miyasaka N, Yamamoto K et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4.
4. Campbell L, Chen C, Bhagat SS et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;50: 552-62.
5. Burmester GR, Feist E, Kellner H et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9.
6. Stokes MB, Foster K, Markowitz GS et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005;20: 1400-6.
7. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology 2009;48:716-20.
8. De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus 2006;15:762-7.
9. Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51.